KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Operating Income (2020 - 2025)

Historic Operating Income for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to -$172.2 million.

  • Recursion Pharmaceuticals' Operating Income fell 7508.39% to -$172.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$723.6 million, marking a year-over-year decrease of 8356.81%. This contributed to the annual value of -$479.0 million for FY2024, which is 3683.48% down from last year.
  • As of Q3 2025, Recursion Pharmaceuticals' Operating Income stood at -$172.2 million, which was down 7508.39% from -$176.2 million recorded in Q2 2025.
  • Over the past 5 years, Recursion Pharmaceuticals' Operating Income peaked at -$30.5 million during Q1 2021, and registered a low of -$191.4 million during Q1 2025.
  • Moreover, its 5-year median value for Operating Income was -$81.7 million (2023), whereas its average is -$94.6 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Operating Income plummeted by 15393.85% in 2021, and later skyrocketed by 612.38% in 2022.
  • Over the past 5 years, Recursion Pharmaceuticals' Operating Income (Quarter) stood at -$65.0 million in 2021, then grew by 6.12% to -$61.0 million in 2022, then crashed by 62.23% to -$98.9 million in 2023, then tumbled by 85.76% to -$183.8 million in 2024, then grew by 6.29% to -$172.2 million in 2025.
  • Its Operating Income was -$172.2 million in Q3 2025, compared to -$176.2 million in Q2 2025 and -$191.4 million in Q1 2025.